4O15
The crystal structure of a mutant NAMPT (S165F) in complex with GNE-618
Summary for 4O15
Entry DOI | 10.2210/pdb4o15/pdb |
Related | 4O13 4O14 4O16 4O17 4O18 4O19 4O1A 4O1B 4O1C 4O1D 4O28 |
Descriptor | Nicotinamide phosphoribosyltransferase, N-(4-{[3-(trifluoromethyl)phenyl]sulfonyl}benzyl)-2H-pyrazolo[3,4-b]pyridine-5-carboxamide, PHOSPHATE ION, ... (5 entities in total) |
Functional Keywords | transferase-transferase inhibitor complex, transferase/transferase inhibitor |
Biological source | Homo sapiens (human) |
Cellular location | Nucleus: P43490 |
Total number of polymer chains | 2 |
Total formula weight | 115491.90 |
Authors | Oh, A.,Coons, M.,Brillantes, B.,Wang, W. (deposition date: 2013-12-15, release date: 2014-10-22, Last modification date: 2024-02-28) |
Primary citation | Wang, W.,Elkins, K.,Oh, A.,Ho, Y.C.,Wu, J.,Li, H.,Xiao, Y.,Kwong, M.,Coons, M.,Brillantes, B.,Cheng, E.,Crocker, L.,Dragovich, P.S.,Sampath, D.,Zheng, X.,Bair, K.W.,O'Brien, T.,Belmont, L.D. Structural Basis for Resistance to Diverse Classes of NAMPT Inhibitors. Plos One, 9:e109366-e109366, 2014 Cited by PubMed Abstract: Inhibiting NAD biosynthesis by blocking the function of nicotinamide phosphoribosyl transferase (NAMPT) is an attractive therapeutic strategy for targeting tumor metabolism. However, the development of drug resistance commonly limits the efficacy of cancer therapeutics. This study identifies mutations in NAMPT that confer resistance to a novel NAMPT inhibitor, GNE-618, in cell culture and in vivo, thus demonstrating that the cytotoxicity of GNE-618 is on target. We determine the crystal structures of six NAMPT mutants in the apo form and in complex with various inhibitors and use cellular, biochemical and structural data to elucidate two resistance mechanisms. One is the surprising finding of allosteric modulation by mutation of residue Ser165, resulting in unwinding of an α-helix that binds the NAMPT substrate 5-phosphoribosyl-1-pyrophosphate (PRPP). The other mechanism is orthosteric blocking of inhibitor binding by mutations of Gly217. Furthermore, by evaluating a panel of diverse small molecule inhibitors, we unravel inhibitor structure activity relationships on the mutant enzymes. These results provide valuable insights into the design of next generation NAMPT inhibitors that offer improved therapeutic potential by evading certain mechanisms of resistance. PubMed: 25285661DOI: 10.1371/journal.pone.0109366 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.8 Å) |
Structure validation
Download full validation report